Jurgi Camblong Sells 43,129 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 43,129 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $4.96, for a total value of $213,919.84. Following the sale, the chief executive officer directly owned 3,664,440 shares in the company, valued at approximately $18,175,622.40. This represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total value of $87,365.00.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.72, for a total value of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total value of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total value of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.77, for a total value of $21,398.22.

SOPHiA GENETICS Price Performance

Shares of SOPH opened at $5.28 on Friday. The company has a market cap of $361.63 million, a P/E ratio of -10.35 and a beta of 1.04. The stock has a fifty day moving average price of $4.76 and a 200 day moving average price of $4.73. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. On average, research analysts forecast that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Guggenheim increased their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, BTIG Research increased their price target on SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, SOPHiA GENETICS presently has an average rating of “Hold” and a consensus target price of $7.50.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Strategic commercial win — Mount Sinai Health System will adopt SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform to support precision cancer care and genomic testing at an NCI-designated center, a high-visibility customer that could drive recurring software usage and credibility in the U.S. market. Mount Sinai collaboration
• Positive Sentiment: Sector reinforcement — coverage of Mount Sinai using AI to speed genomic testing underscores demand for AI-driven genomics platforms, supporting the case for broader SOPHiA DDM adoption and long-term revenue potential. Healthcare IT News
• Positive Sentiment: Analyst backing — recent analyst notes have raised price targets and issued buy ratings (e.g., BTIG, Guggenheim), giving investors a visible upside reference versus current levels and likely contributing to bullish sentiment.
• Neutral Sentiment: Insider selling disclosed — multiple insiders (CEO, President and others) sold tens of thousands of shares in mid‑April under pre‑arranged Rule 10b5‑1 plans, largely to cover tax withholding on vested awards. These are scheduled/tax-related sales (increasing float but not necessarily signaling negative inside-view). SEC Form 4 (example)
• Negative Sentiment: Profitability concerns persist — SOPH reported a March-quarter EPS miss (reported ($0.28) vs. consensus ($0.20)), negative margins and a large negative ROE; analysts still expect FY losses (~-0.96 EPS), which can cap valuation expansion despite commercial progress. Earnings & metrics

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Savvy Advisors Inc. purchased a new stake in shares of SOPHiA GENETICS during the third quarter valued at $48,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS during the third quarter valued at $49,000. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at $49,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at $54,000. Finally, XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at $55,000. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.